Compare CIX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | CGEN |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.7M | 270.4M |
| IPO Year | 1997 | 2001 |
| Metric | CIX | CGEN |
|---|---|---|
| Price | $23.29 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 1.7K | ★ 567.7K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | ★ 9.48% | N/A |
| EPS Growth | ★ 17.04 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $158,285,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $48.14 | ★ N/A |
| Revenue Growth | ★ 8.46 | N/A |
| 52 Week Low | $20.29 | $1.30 |
| 52 Week High | $32.30 | $3.24 |
| Indicator | CIX | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 49.11 |
| Support Level | $22.86 | $2.54 |
| Resistance Level | $23.36 | $3.24 |
| Average True Range (ATR) | 0.47 | 0.17 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 35.40 | 29.17 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.